Gloria León-Ávila

Dr. Gloria León-Ávila

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Journal of Proteomics
Verified
Journal Article
Closed access
KCKarla Grisel Calderón-González
Karla Grisel Calderón-González
MVMaria Luz Valero
Maria Luz Valero
MLMaria Luisa Labra-Barrios
Maria Luisa Labra-Barrios
CBCésar Isaac Bazán-Méndez
César Isaac Bazán-Méndez
ATAlejandra Tavera-Tapia
Alejandra Tavera-Tapia
JLJuan Pedro Luna-Arias
Juan Pedro Luna-Arias

3 November 2018 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
MHMario Hidalgo-Ruiz
Mario Hidalgo-Ruiz
Carlos E. SuárezCarlos E. Suárez
Carlos E. Suárez
MMMiguel Angel Mercado-Uriostegui
Miguel Angel Mercado-Uriostegui
RHRUBEN HERNANDEZ-ORTIZ
RUBEN HERNANDEZ-ORTIZ
JRJuan Alberto Ramos
Juan Alberto Ramos
Juan MosquedaJuan Mosqueda
Juan Mosqueda
Babesia bovis belongs to the phylum Apicomplexa and is the major causal agent of bovine babesiosis, the most important veterinary disease transmitted by arthropods. In apicomplexan parasites, the interaction between AMA1 and RON2 is necessary for the invasion process, and it is a target for vaccine development. In B. bovis, the existence of AMA1 has already been reported; however, the presence of a homolog of RON2 is unknown. The aim of this study was to characterize RON2 in B. bovis. The B. bovis ron2 gene has a similar synteny with the orthologous gene in the B. bigemina genome. The entire ron2 gene was sequenced from different B. bovis strains showing > 99% similarity at the amino acid and nucleotide level among all the sequences obtained, including the characteristic CLAG domain for cytoadherence in the amino acid sequence, as is described in other Apicomplexa. The in silico transcription analysis showed similar levels of transcription between attenuated and virulent B. bovis strains, and expression of RON2 was confirmed by western blot in the B. bovis T3Bo virulent strain. Four conserved peptides, containing predicted B-cell epitopes in hydrophilic regions of the protein, were designed and chemically synthesized. The humoral immune response generated by the synthetic peptides was characterized in bovines, showing that anti-RON2 antibodies against peptides recognized intraerythrocytic merozoites of B. bovis. Only peptides P2 and P3 generated partially neutralizing antibodies that had an inhibitory effect of 28.10% and 21.42%, respectively, on the invasion process of B. bovis in bovine erythrocytes. Consistently, this effect is additive since inhibition increased to 42.09% when the antibodies were evaluated together. Finally, P2 and P3 peptides were also recognized by 83.33% and 87.77%, respectively, of naturally infected cattle from endemic areas. The data support RON2 as a novel B. bovis vaccine candidate antigen that contains conserved B-cell epitopes that elicit partially neutralizing antibodies.

18 August 2022 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Open access
NRNora E. Regino-Zamarripa
Nora E. Regino-Zamarripa
GRGustavo Ramirez
Gustavo Ramirez
LJLuis Armando Jiménez-Álvarez
Luis Armando Jiménez-Álvarez
ACAlfredo Cruz-Lagunas
Alfredo Cruz-Lagunas
IGItzel Alejandra Gómez-García
Itzel Alejandra Gómez-García
JZJoaquín Zúñiga
Joaquín Zúñiga
Interferon-induced transmembrane (IFITM) proteins mediate protection against enveloped viruses by blocking membrane fusion at endosomes. IFITM1 and IFITM3 are crucial for protection against influenza, and various single nucleotide polymorphisms altering their function have been linked to disease susceptibility. However, bulk IFITM1 and IFITM3 mRNA expression dynamics and their correlation with clinical outcomes have not been extensively addressed in patients with respiratory infections. In this study, we evaluated the expression of IFITM1 and IFITM3 in peripheral leukocytes from healthy controls and individuals with severe pandemic influenza A(H1N1) or coronavirus disease 2019 (COVID-19). Comparisons between participants grouped according to their clinical characteristics, underlying disease, and outcomes showed that the downregulation of IFITM1 was a distinctive characteristic of severe pandemic influenza A(H1N1) that correlated with outcomes, including mortality. Conversely, increased IFITM3 expression was a common feature of severe pandemic influenza A(H1N1) and COVID-19. Using a high-dose murine model of infection, we confirmed not only the downregulation of IFITM1 but also of IFITM3 in the lungs of mice with severe influenza, as opposed to humans. Analyses in the comparative cohort also indicate the possible participation of IFITM3 in COVID-19. Our results add to the evidence supporting a protective function of IFITM proteins against viral respiratory infections in humans.

13 October 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
CMClaudia M. Malagón-Reyes
Claudia M. Malagón-Reyes
ITItzhel Garcia Torres
Itzhel Garcia Torres
YMYoalli Martínez-Pérez
Yoalli Martínez-Pérez
SESergio Enriquez-Flores
Sergio Enriquez-Flores
T-cell acute lymphoblastic leukemia (T-ALL) is a challenging childhood cancer to treat, with limited therapeutic options and high relapse rates. This study explores deamidated triosephosphate isomerase (dTPI) as a novel therapeutic target. We hypothesized that selectively inhibiting dTPI could reduce T-ALL cell viability without affecting normal T lymphocytes. Computational modeling and recombinant enzyme assays revealed that disulfiram (DS) and curcumin (CU) selectively bind and inhibit dTPI activity without affecting the non-deamidated enzyme. At the cellular level, treatment with DS and CU significantly reduced Jurkat T-ALL cell viability and endogenous TPI enzymatic activity, with no effect on normal T lymphocytes, whereas the combination of sodium dichloroacetate (DCA) with DS or CU showed synergistic effects. Furthermore, we demonstrated that dTPI was present and accumulated only in Jurkat cells, confirming our hypothesis. Finally, flow cytometry confirmed apoptosis in Jurkat cells after treatment with DS and CU or their combination with DCA. These findings strongly suggest that targeting dTPI represents a promising and selective target for T-ALL therapy.

16 July 2013 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
APArmando Pérez-Rangel
Armando Pérez-Rangel
JHJosé Manuel Hernández
José Manuel Hernández
ACAraceli Castillo-Romero
Araceli Castillo-Romero
LYLilián Yépez-Mulia
Lilián Yépez-Mulia
RCRafael Castillo
Rafael Castillo
LILilián
Lilián

30 January 2021 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
OROmar Rojas-Gutiérrez
Omar Rojas-Gutiérrez
APArmando Pérez-Rangel
Armando Pérez-Rangel
ACAraceli Castillo-Romero
Araceli Castillo-Romero
JTJosé Tapia-Ramírez
José Tapia-Ramírez
Emmanuel Ríos-CastroEmmanuel Ríos-Castro
Emmanuel Ríos-Castro
JHJosé Manuel Hernández
José Manuel Hernández